Recruiting

Testing a new immune-clearing treatment for lupus and arthritis

Plain-English translation of NCT07237659 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This study is testing a new medication called NTR-1011 designed to help reduce harmful inflammation in people with systemic lupus erythematosus (lupus) or rheumatoid arthritis. The medication works by clearing away sticky web-like structures that immune cells release, which can build up and cause tissue damage in these diseases. The trial is measuring whether this treatment is safe and whether it helps reduce inflammation in patients.

In lupus and rheumatoid arthritis, the body's immune system becomes overactive and releases structures that normally help fight infection, but instead cause harmful inflammation and tissue damage when they accumulate. This medication is being tested to see if it can safely clear away these structures and reduce the inflammation that damages joints and organs.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with lupus for at least 6 months (or rheumatoid arthritis for at least 3 months) and your disease is currently active
you have specific blood test results showing your lupus or arthritis is active (such as positive lupus antibodies or low complement levels for lupus, or positive rheumatoid factor for arthritis)
you are already taking stable standard treatment for your condition, such as antimalarial drugs, low-dose corticosteroids, or conventional disease-modifying medications
you are able to use highly effective birth control during and after the study and are willing to attend study visits regularly

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use effective contraception
you have had cancer within the past year
you have severe kidney, liver, or lung disease, uncontrolled high blood pressure, or recent heart attacks or strokes
you have an active infection, untreated tuberculosis, or chronic hepatitis B
you received a live vaccine in the past 4 weeks or plan to receive one within 4 weeks after finishing the study

What participation looks like

If you join the patient portion of this study, you will receive the medication through an IV infusion while continuing your regular lupus or arthritis medications. You'll come to the clinic multiple times for appointments where doctors will check your health, do blood tests, and monitor how you're responding to the treatment. The entire study typically lasts several weeks to months, and your main responsibility is attending scheduled visits and reporting any side effects or changes in how you feel.

Testing a new immune-clearing treatment for lupus and arthritis

What is this trial?

Do you qualify?

What participation looks like

Trial locations(7 sites)